Unicycive is a biotechnology company developing drug candidates for kidney disease, including treatments for dialysis patients. It last closed at $3.70 on Nov 17, up 0.00% on the day.
Only 1 firm rated UNCY in the past 90 days, not enough for a consensus
Average 12-month target
$13.00
▲ 251.4% upside
Based on 1 analyst who set a price target on UNCY in the past 90 days. The average target is $13.00, with a high of $13.00 and a low of $13.00, compared with the last close of $3.70.
Low $13.00Avg $13.00High $13.00
Blue marker: last close $3.70
Highest target$13.00
Average target$13.00
Lowest target$13.00
Latest rating changes
HC Wainwright & Co.Target lowered
Sep 29Buy$15 → $13
GuggenheimMaintained
Aug 13Buy$25
B. Riley SecuritiesTarget lowered
Aug 13Buy$22 → $20
BenchmarkTarget lowered
Jul 1Buy$18 → $13
Noble Capital MarketsMaintained
Jul 1Buy$50
Date
Firm
Action
Rating
Price target
Sep 29
HC Wainwright & Co.
Target lowered
Buy
$15 → $13
Aug 13
Guggenheim
Maintained
Buy
$25
Aug 13
B. Riley Securities
Target lowered
Buy
$22 → $20
Jul 1
Benchmark
Target lowered
Buy
$18 → $13
Jul 1
Noble Capital Markets
Maintained
Buy
$50
Loading…
Technical Analysis
UNCY · as of the Nov 17 close · updated after every close
Downtrend
The stock sits between its 20 and 50 day averages. It is 60% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 47). The nearest support is the 20 day average at $3.69, and the nearest resistance the Pivot R1 at $3.78.
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 6.1%/day
Key levels
$8.7452 week high+136.2%
$5.92200 day average+60.0%
$4.73100 day average+27.8%
$4.1450 day average+11.9%
$3.85Swing high (Nov 11)+4.1%
$3.78Pivot R1+2.2%
$3.70Last close
$3.6920 day average−0.3%
$3.69Pivot−0.3%
$3.61Pivot S1−2.4%
$3.48Swing low (Oct 27)−5.9%
$3.3352 week low−10.0%
Indicators
RSI (14)
46.61
Middle of its range
Neutral
MACD
-0.12
Above its signal line
Bullish
Stochastic
53.3
Middle of its range
Neutral
ADX (14)
26.0
Trending down
Williams %R
-38.3
Oversold below −80, overbought above −20
Neutral
CCI (20)
1.3
Oversold below −100, overbought above 100
Neutral
Rate of change
+3.1%
Change over 10 sessions
Bullish
ATR (14)
$0.23
Typical daily range, 6.1% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityLow, 18.4%/day
Key levels
$8.7452 week high+136.2%
$5.92200 day average+60.0%
$4.73100 day average+27.8%
$4.1450 day average+11.9%
$3.85Swing high (Nov 11)+4.1%
$3.78Pivot R1+2.2%
$3.70Last close
$3.6920 day average−0.3%
$3.69Pivot−0.3%
$3.61Pivot S1−2.4%
$3.48Swing low (Oct 27)−5.9%
$3.3352 week low−10.0%
Indicators
RSI (14)
34.91
Weak, oversold below 30
Neutral
MACD
-0.71
Below its signal line
Bearish
Stochastic
10.7
Near the bottom of its range
Oversold
ADX (14)
30.3
Trending down
Williams %R
-85.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-97.0
Oversold below −100, overbought above 100
Neutral
Rate of change
−30.1%
Change over 10 sessions
Bearish
ATR (14)
$0.68
Typical daily range, 18.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for UNCY
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how UNCY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow UNCY usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How UNCY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether UNCY is in one of them and how their past UNCY trades turned out.
Unicycive is a biotechnology company based in Mountain View, California, that is developing drugs for kidney disease. Its lead candidate, oxylanthanum carbonate, is a tablet meant to control high phosphorus levels in patients on dialysis, and it is designed to be swallowed whole rather than chewed. Its second candidate, UNI-494, is in development for acute kidney injury, a condition for which no FDA approved medicines currently exist. The company plans to seek approvals in the United States and to partner with other drugmakers in other markets.